Gilead Sciences, Inc. $GILD Stock: Knights of Columbus Asset Advisors LLC Increases Position

Knights of Columbus Asset Advisors LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 114,329 shares of the biopharmaceutical company’s stock after buying an additional 4,617 shares during the period. Gilead Sciences makes up approximately 0.8% of Knights of Columbus Asset Advisors LLC’s portfolio, making the stock its 24th biggest holding. Knights of Columbus Asset Advisors LLC’s holdings in Gilead Sciences were worth $17,041,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Philadelphia Trust Co. increased its position in shares of Gilead Sciences by 14.3% during the 3rd quarter. Philadelphia Trust Co. now owns 4,347 shares of the biopharmaceutical company’s stock valued at $648,000 after purchasing an additional 545 shares during the last quarter. Moneco Advisors LLC boosted its holdings in shares of Gilead Sciences by 2.4% in the 3rd quarter. Moneco Advisors LLC now owns 3,913 shares of the biopharmaceutical company’s stock worth $583,000 after buying an additional 91 shares during the last quarter. Mesirow Financial Investment Management Inc. boosted its holdings in shares of Gilead Sciences by 10.8% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 7,559 shares of the biopharmaceutical company’s stock worth $1,127,000 after buying an additional 734 shares during the last quarter. Lido Advisors LLC grew its position in Gilead Sciences by 3.5% during the third quarter. Lido Advisors LLC now owns 159,191 shares of the biopharmaceutical company’s stock valued at $23,728,000 after buying an additional 5,366 shares during the period. Finally, Keybank National Association OH grew its position in Gilead Sciences by 1.8% during the third quarter. Keybank National Association OH now owns 130,028 shares of the biopharmaceutical company’s stock valued at $19,381,000 after buying an additional 2,329 shares during the period. 83.67% of the stock is owned by institutional investors.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Recent coverage highlights improving growth across Gilead’s business and strong recent results. Its latest reported quarter beat consensus on both earnings and revenue, with revenue up 6.8% year over year. This supports the positive investment case behind the stock’s advance toward a 52-week high. Article: Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
• Positive Sentiment: Analysts have recently raised price targets, including JPMorgan and Wells Fargo to $190, and maintained positive ratings—potential support for investor sentiment. Gilead Sciences analyst and stock information
• Neutral Sentiment: Gilead partner Xilio Therapeutics said it expects to deliver an option data package for its investigational cancer drug efarindodekin alfa to Gilead in the first half of 2027. Any value to Gilead depends on future data and potential payments; the update does not establish a near-term financial benefit. Xilio Therapeutics pipeline update
• Negative Sentiment: An executive vice president sold 3,399 shares, reducing his holdings by about 39%. The sale was made under a pre-arranged trading plan, which may limit its significance as a signal about the company’s outlook. Gilead Sciences insider-trading report
• Negative Sentiment: Vir, a competitor in hepatitis D, reported positive results for its experimental treatment. The news could raise competitive concerns, though the supplied report does not indicate an immediate impact on Gilead’s business. Vir rival advances hepatitis D treatment

Gilead Sciences Stock Up 0.9%

GILD stock opened at $170.87 on Wednesday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. The company has a market capitalization of $211.94 billion, a price-to-earnings ratio of -54.07 and a beta of 0.35. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The stock has a fifty day moving average of $154.00 and a 200-day moving average of $141.34.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same period in the previous year, the business posted $2.47 EPS. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, equities research analysts predict that Gilead Sciences, Inc. will post -1.07 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -103.80%.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the transaction, the director owned 10,066 shares in the company, valued at $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Keeley Cain Wettan sold 3,399 shares of the business’s stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $164.11, for a total transaction of $557,809.89. Following the completion of the sale, the executive vice president directly owned 5,360 shares in the company, valued at approximately $879,629.60. This trade represents a 38.81% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 242,709 shares of company stock valued at $39,503,427. 0.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on GILD. Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a report on Friday, October 30th. UBS Group boosted their target price on shares of Gilead Sciences from $175.00 to $195.00 and gave the company a “buy” rating in a research note on Friday, October 30th. HSBC boosted their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Finally, Zacks Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $170.15.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.